Morbid Obesity Clinical Trial
Official title:
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Abstract:
Fatty liver most frequently corresponds to a fat overload of the liver. It is usually
classified as alcoholic steatosis or non-alcoholic steatosis. In the case of non alcoholic
fatty liver overload, the histological spectrum ranges from simple steatosis to
steatohepatitis (NASH) which associates inflammation to steatosis, with a risk of progression
to fibrosis and cirrhosis. Obese patients are at particular risk of NASH. Screening of these
hepatic lesions is difficult especially as they may exist while the liver tests are normal.
The diagnosis of NASH is currently done by liver biopsy, which exposes them in particular to
the risk of hemorrhagic complications.
Number of subjects required:
According to the literature and data collected Louis Mourier in the recent years, the
inclusion of 200 patients would examine 20-40 patients with severe histological steatosis and
steatohepatitis. All patients will be included in Louis Mourier hospital.
Follow-up: one month Search duration: 37 months Duration inclusions: 36 months The total
duration of participation for a patient will be one month.
Methodology:
It is a monocentric, prospective study evaluating the value of noninvasive tests for the
diagnosis of hepatic lesions in morbid obese patients. The "open " MRI system allows access
to MRI for all obese patients (maximum weight 250 kg). Three of such systems are available in
France and liver pathology can be explored only on the system of Louis Mourier.
The reference method is liver histology; studied tests are abdominal MRI, Fibroscan / CAP,
and serum tests.
Examinations required specifically for research Examinations required specifically for the
research is abdominal MRI, FibroScan/ CAP and serum tests.
Primary endpoint :
To validate the use of abdominal MRI, the FibroScan/ CAP and serum tests for finding severe
steatosis and / or NASH, specificity, sensitivity, positive and negative predictive values of
these tests are calculated. The gold standard is the result of histology on liver biopsy,
with a morphometric study of these parameters. ROC curves are used to determine the best
compromise between sensitivity and specificity.
The secondary endpoints were:
Histological lesions of liver fibrosis. Quantification of abdominal fat by MRI (in the form
of three variables of interest: quantification of the surface of the visceral fat, of
subcutaneous fat and of intrahepatic fat assessed by the percentage loss of signal
Main objective :
The main objective of the study was to determine in patients with morbid obesity waiting for
bariatric surgery, the accuracy of non-invasive tests for diagnosis of severe steatosis and /
or NASH.
The gold standard is liver biopsy with a morphometric study.
Non-invasive tests will be used:
- Serum tests: the FibroMax (which includes the NASH test, FibroTest and SteatoTest) and
FibroMeter.
- Radiological examinations: MRI and FibroScan / CAP
Secondary objectives :
The secondary objectives are:
1. to determine the accuracy of these non-invasive tests for the diagnosis of severe
steatosis alone, steatohepatitis (NASH or) and hepatic fibrosis
2. to determine the best combination of these tests to better evaluate the presence of
severe steatosis, NASH and a hepatic fibrosis.
3. to quantify MRI visceral and subcutaneous fat in morbidly obese patients
Research Design :
1. Judging Criteria
Primary endpoint To validate the use of serum tests, FibroScan / CAP abdominal MRI for
the diagnosis of severe steatosis and / or NASH (specificity, sensitivity, positive and
negative predictive values). The gold standard is the result of histology on liver
biopsy, with a morphometric study. For each diagnostic test, a ROC curve is used to
determine the best compromise between sensitivity and specificity.
The histological diagnosis of severe steatosis is defined by the presence of hepatic
steatosis grade 3 or higher. The diagnosis of NASH is defined by the presence of lobular
inflammation with neutrophils and hepatocytes ballooning.
Secondary endpoints
- Histological lesions of liver fibrosis Quantification of abdominal fat by MRI (in the
form of three variables of interest: quantification of the surface of the visceral fat
from the surface of the subcutaneous fat and the amount of intrahepatic fat assessed by
the percentage loss of signal).
2. Methodology and expected number of patients in research
This is a prospective study evaluating the value of noninvasive tests for the diagnosis
of hepatic lesions in morbid obese patients. The MRI system "open" allows access to
obese patients. Three such systems are available in France and liver pathology is
supported only on the system of Louis Mourier.
The reference method is liver histology; tests studied are MRI abdominal Fibroscan /
CAP, and serum tests (FibroTest, FibroMeter, SteatoTest, NASH test).
The study will be conducted in 200 obese patients who will have a liver biopsy performed
during bariatric surgery:
- Tests for the detection of steatosis (fat quantification of intrahepatic MRI
measurement of steatosis by CAP, serum tests) and evaluating histological steatosis
(main objective)
- Tests for the detection of NASH (test serum) and histology
- Tests of fibrosis (serum tests; FibroScan) and histological data assessing
fibrosis.
The duration and extent of obesity (BMI) and biological data (HOMA-test) will be taken
into account.
3. Examinations required specifically for research
Liver biopsy is routinely performed intraoperatively in the routine monitoring of
patients for bariatric surgery, examinations specific to the research are:
- Serum tests
- FibroScan / CAP
- Abdominal MRI
Risk / risk absences The sting at blood sampling can cause the formation of a small
hematoma without gravity, which will subside spontaneously within a few days.
FibroScan ® / CAP presents no risk of side effects. Liver MRI shows no risk if the
cons-indications are respected. Wearing a stack (pacemaker) or any element that contains
the iron near the eyes or head are contra-indications as are a major risk factor (risk
of death, blindness). The presence of a heart valve or a stent (also called metal
prosthesis) is not an absolute contra-indication-and their compatibility with MRI will
be verified before completion of the examination, as is the case in practice clinic ..
Liver biopsy, which is part of the examinations carried out in a systematic way without
any protocol adds no additional risk to the surgical
4. Study site
The study will be conducted at Louis Mourier, a reference center for the treatment of
obesity, which has an open system allowing access to obese.
5. Indications for bariatric surgery
Indications for bariatric surgery at Louis Mourier, a reference center for the treatment of
obesity, are consistent with the recommendations of the HAS in 2009, based on professional
consensus.
Surgery is indicated in patients with all of the following criteria:
1. BMI ≥ 40 or BMI ≥ 35 with comorbid
2. failure (s) prior (s) of the conventional treatment of obesity combined dietary,
physical activity and behavioral therapy
3. appraisal nutritionally: global, personal and non-surgical
4. considered only after medical treatment for a minimum of 1 year
5. well-informed and motivated patients, with acceptable surgical risks
6. obesity stable (or worsening) for five years
7. absence of endocrine pathology (adrenal, thyroid) may be due to obesity
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03657927 -
A Comparison of McGrath MAC Versus C-MAC Videolaryngoscopes in Morbidly Obese Patients
|
N/A | |
Recruiting |
NCT04934826 -
Comparison of the Absorption of Hydrolyzed or Intact Proteins in Morbid Obese Patients After the Roux Y Gastric Bypass
|
N/A | |
Completed |
NCT03181347 -
The Microbiology of Bariatric Surgery
|
N/A | |
Completed |
NCT03886870 -
Obesity, Lifestyle and Work Intervention
|
N/A | |
Active, not recruiting |
NCT04433338 -
The PREBA Study: Effect of Preoperative Weight Loss With a 14-day Low-calorie Diet on Surgical Procedure and Outcomes in Patients Undergoing RYGB Surgery
|
N/A | |
Completed |
NCT03553849 -
Utilization of Very Low Calorie Diet in Obese General Surgery Patients
|
N/A | |
Completed |
NCT05854875 -
Diabetes Remission After RYGBP and RYGBP With Fundus Resection
|
N/A | |
Not yet recruiting |
NCT03203161 -
Registry on Obesity Surgery in Adolescents
|
||
Not yet recruiting |
NCT03601273 -
Bariatric Embolization Trial for the Obese Nonsurgical
|
Phase 1 | |
Recruiting |
NCT02129296 -
Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01564732 -
Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding
|
N/A | |
Completed |
NCT02033265 -
Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity
|
||
Not yet recruiting |
NCT01652105 -
Randomized Trial of Preoperative Diets Before Bariatric Surgery
|
N/A | |
Completed |
NCT01963637 -
Gastric Volumetry by Gastric Tomodensitometry With Gas
|
N/A | |
Completed |
NCT01955993 -
Fentanyl Metabolism in Obese Adolescents
|
N/A | |
Completed |
NCT01149512 -
Outcomes of the Adjustable Gastric Band in a Publicly Funded Obesity Program
|
N/A | |
Terminated |
NCT01759550 -
Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
|
||
Recruiting |
NCT01685177 -
Single Anastomosis Duodeno-Ileal Bypass vs Standard Duodenal Switch as a Second Step After Sleeve Gastrectomy in the Super-Morbid Obese Patient
|
N/A | |
Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
Completed |
NCT02414893 -
Hunger/Satiety's Physiopathologic Study in Morbidly Obese Patients
|
N/A |